SEC For	m 4 FORM	4	UNITE) STA	TES S	ECURITI	ES) E)	КСНА	NGE	со	MMI	SSION					
						Washington, D.C. 20549									OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See					AT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									HIP	Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person* PEPIN RONALD					Celld	2. Issuer Name and Ticker or Trading Symbol <u>Celldex Therapeutics, Inc.</u> [CLDX]									of Reportin cable) r (give title	ve title Othe		Owner r (specify	
(Last) C/O CEI	ast) (First) (Middle) /O CELLDEX THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/15/2023									X Oncer (give tute below) below) SR. VP & CBO					
53 FRONTAGE ROAD, SUITE 220					4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) HAMPT	treet) IAMPTON NJ 08827													X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Che	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											ed to		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date if any (Month/Day/Yea	′ c	Transact Code (In		4. Securi Disposed 5)	. Securities Acquired (A isposed Of (D) (Instr. 3,)		A) or 3, 4 and	Beneficia	es ally Following	Form (D) o	vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						c	Code	v	Amount	(A) (D)) or)	Price Transaction (Instr. 3 and		tion(s)					
		1				urities Acc s, warrant								Owned			^		
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution or Exercise (Month/Day/Year) if any		Date, 1	I. Fransaction Code (Instr. 3)		6. Date Exercisab Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	s Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)		

Explanation of Responses: 1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

/s/ Samuel B. Martin, attorneyin-fact for Ronald A. Pepin,

Amount or Number of Shares

15,000

\$<mark>0</mark>

Ph.D.

Title

Common Stock

Expiration Date

06/15/2033

Date

Exercisable

06/15/2024⁽²⁾

(D)

** Signature of Reporting Person Date

15,000

06/20/2023

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

 $06/15/2023^{(1)}$

Incentive Stock Option (right to buy)⁽¹⁾

\$36.87

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

v Code

Α

(A)

15,000

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.